376 related articles for article (PubMed ID: 27919477)
1. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
Roar M; Illes Z; Sejbaek T
Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
3. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
[TBL] [Abstract][Full Text] [Related]
4. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS).
Charvet LE; Beekman R; Amadiume N; Belman AL; Krupp LB
J Neurol Sci; 2014 Jun; 341(1-2):79-84. PubMed ID: 24792098
[TBL] [Abstract][Full Text] [Related]
5. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
6. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.
Morrow SA; O'Connor PW; Polman CH; Goodman AD; Kappos L; Lublin FD; Rudick RA; Jurgensen S; Paes D; Forrestal F; Benedict RH
Mult Scler; 2010 Nov; 16(11):1385-92. PubMed ID: 20739335
[TBL] [Abstract][Full Text] [Related]
9. Deconstructing the symbol digit modalities test in multiple sclerosis: The role of memory.
Patel VP; Walker LAS; Feinstein A
Mult Scler Relat Disord; 2017 Oct; 17():184-189. PubMed ID: 29055455
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
[TBL] [Abstract][Full Text] [Related]
11. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
12. The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis.
Van Schependom J; D'hooghe MB; Cleynhens K; D'hooge M; Haelewyck MC; De Keyser J; Nagels G
Eur J Neurol; 2014 Sep; 21(9):1219-25, e71-2. PubMed ID: 24850580
[TBL] [Abstract][Full Text] [Related]
13. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study.
Talmage GD; Coppes OJM; Javed A; Bernard J
PLoS One; 2017; 12(4):e0173299. PubMed ID: 28426702
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
16. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH
J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
Manouchehrinia A; Larsson H; Karim ME; Lycke J; Olsson T; Kockum I
Mult Scler; 2023 Apr; 29(4-5):628-636. PubMed ID: 36789885
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
20. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
